Probatebeta
Target

PDCD1

Programmed cell death protein 1

As of the edition of 20 October 2026, PDCD1 (programmed cell death protein 1, UniProt Q15116) has 53 drugs tested at it and 95 companies on the list, 12 on route A and 11 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
Q15116
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
38
Disease areas
Cancer; Digestive system; Lungs and airways; Skin and connective tissue; Urinary and reproductive; Pregnancy and women's health; Hormones; Blood and lymph
Registered trials of its drugs
7,048

Drugs at this target

StatusCount
Marketed9
Active23
Went quiet2
Stopped8
Status not established11
Total53
DrugStatusFurthest phaseUS protection
PembrolizumabMarketedPhase 4Ends 2031
NivolumabMarketedPhase 4Ends 2031
TislelizumabMarketedPhase 4Ends 2036
ToripalimabMarketedPhase 4Ends 2035
SintilimabActivePhase 4none listed
CamrelizumabActivePhase 4none listed
CemiplimabMarketedPhase 3Ends 2030
CadonilimabActivePhase 3none listed
SerplulimabMarketedPhase 4none listed
DostarlimabMarketedPhase 4Ends 2033
RetifanlimabMarketedPhase 3Ends 2035
ZimberelimabActivePhase 3none listed

12 of 53 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A12
Route B11
Engaged65
Undetermined7
Total on the list95
Three companies on route A or B, with the route only
CompanyRoute
Bristol Myers SquibbRoute B
Merck & Co.Route B
Coherus OncologyRoute B

The other 92 companies at PDCD1

In the product

95 companies in all; 92 are not named here, and no score is.

See the 95 companies at PDCD1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at PDCD1

Other targets in cancer

Companies holding approvals at PDCD1